INTRODUCTION
============

Liver magnetic resonance imaging (MRI) with hepatobiliary contrast agents such as gadoxetic acid or gadobenate dimeglumine has been increasingly used for the evaluation of focal liver lesions in recent years, as it provides strong lesion-to-liver contrast via hepatocyte-specific uptake during the hepatobiliary phase ([@B1][@B2]). In particular, there is ample evidence demonstrating the diagnostic value of gadoxetic acid-enhanced MRI for the detection of small hepatocellular carcinomas (HCCs) ([@B3]), and for the differentiation between HCCs and other hepatic lesions or hypervascular pseudolesions ([@B2]). Thus, at present, several recent guidelines include gadoxetic acid-enhanced MRI as a primary diagnostic imaging modality for HCC along with extracellular contrast media-enhanced dynamic contrast-enhanced CT and MRI ([@B4][@B5][@B6][@B7]). However, obtaining the arterial phase at sufficient quality is more challenging in gadoxetic acid-enhanced liver MRI, due to the narrow time window of the arterial phase resulting from the smaller amount of the standard dose ([@B8]), as well as a high incidence of transient dyspnea in comparison with extracellular contrast agents ([@B9][@B10]). Therefore, in order to improve the gadoxetic acid-enhanced MRI quality of the arterial phase, several strategies have been suggested including slowing down the injection rate to prolong the arterial phase ([@B11][@B12]), the use of double-dose gadoxetic acid ([@B13]), and reduction of the scan acquisition time ([@B9][@B14]). However, reduction of the injection rate may lead to unintended reduction of the peak enhancement degree; in addition, administration of double-dose gadoxetic acid reportedly increases the incidence of transient dyspnea ([@B15]) ruining the image quality of the arterial phase. Furthermore, reduction of the scan acquisition time often has a trade-off with decreased spatial resolution and signal-to-noise ratio (SNR), which may lead to less diagnostic images ([@B9][@B16]).

Recently, several techniques of parallel imaging and viewsharing ([@B16][@B17][@B18][@B19][@B20]) or non-Cartesian acquisition ([@B20][@B21][@B22]) have been applied to contrast-enhanced dynamic MRI, so as to achieve high spatio-temporal resolution, which would potentially improve the overall arterial image quality at gadoxetic-enhanced MRI. Although the use of twodimensional (2D) parallel imaging techniques facilitates acquisition of spatial resolution three-dimensional (3D) T1-gradient-echo (GRE) sequences at reduced acquisition time while controlling unwrapping artifacts, reduced SNR is inevitable due to reduced number of acquired echoes compared with conventional 3D T1 GRE sequence ([@B23][@B24]). Although non-Cartesian acquisition schemes are robust to motion artifacts, their imaging characteristics are rather different from standard 3D GRE techniques with Cartesian acquisition and require longer reconstruction times and higher computational hardware demands ([@B21][@B22]). Until now, there have been a few studies dealing with multiple arterial phase acquisition using the Cartesian acquisition scheme that did not need to compromise spatial resolution ([@B16][@B25]). Hadizadeh et al. ([@B18]) recently reported that viewsharing in keyhole imaging and the 2D parallel imaging technique with high reduction factors could allow for increased spatial and temporal resolution in time-resolved MR angiography in the brain. However, to our knowledge, there has been no study regarding the clinical benefit of the high spatial resolution multi-arterial phase using this combination of techniques performed in a large population with liver diseases in comparison with single arterial phase acquisition in combination with MR fluoroscopy. Thus, the purpose of this study was to determine whether triple arterial phase (TAP) imaging can improve arterial phase imaging with high spatial resolution in comparison to single arterial phase acquisition on gadoxetic-acid enhanced MRI.

MATERIALS AND METHODS
=====================

This retrospective study was approved by our Institutional Review Board and the requirement for informed consent was waived.

Study Population
----------------

From October 2012 to January 2013, a total of 752 consecutive patients (M:F = 504:248; mean age, 60.4 years for men and 59.7 years for women) ([Table 1](#T1){ref-type="table"}) were referred to our MR units for routine contrast-enhanced liver MRI according to radiology database search. All patients underwent gadoxetic-acid enhanced liver MR using three different scanners of our institution as scheduled. Among them, 21.9% (165/752) underwent liver MRI with TAP acquisition at a 3T scanner (Ingenia, Philips Healthcare, Best, the Netherlands), and the others underwent liver MRI with a single arterial phase at either 3T (33.0%, 248/752; Magnetom Verio, Siemens Healthcare, Erlangen, Germany) or 1.5T (45.1%, 339/752; Signa HDx, GE Healthcare, Wakesha, IL, USA) scanners depending on the scanners\' availability for time-resolved T1-weighted 3D GRE sequences, which can be used for acquiring multiphasic arterial phase imaging during the study period. Between the two groups, there were no significant differences in demographics except for the high incidence of chronic liver disease in the single arterial acquisition group (*p* = 0.03) and higher incidence of oncology patients in the TAP acquisition group (*p* = 0.005) ([Table 1](#T1){ref-type="table"}).

MR Examination
--------------

The routine liver MR sequence consisted of precontrast heavily T2-weighted images, diffusion weighted images, precontrast T1-weighted images (T1WI) and dynamic contrast-enhanced T1WI, regardless of the scanner type. After intravenous injection of a standard dose of contrast media (0.025 mmol/kg, Primovist or Eovist, Bayer Healthcare, Berlin, Germany) at 1.5 mL/sec followed by 25 mL saline chaser, arterial, portal venous, transitional and hepatobiliary phases were obtained. In all scanners, arterial phase timing was determined under MR fluoroscopy guidance ([@B26]) as each vendor recommended. In scanner 1, 2D fluoroscopy slice was positioned in descending aorta and monitored every second, and arterial phase is acquired when the descending aorta enhances. In scanner 2, right atrium is monitored every second after contrast media injection, and arterial phase is scanned eight seconds later right atrium shows enhancement. In scanner 3, descending aorta signal intensity reaches to a predefined level using dynamic care bolus, arterial phase is scanned. Detailed scanning parameters of the arterial phase in each scanner were listed in [Table 2](#T2){ref-type="table"}. In one scanner (Ingenia, Philips Healthcare, Best, the Netherlands), three arterial phases were obtained in 165 patients in one breath-hold, and the three arterial phases were referred as 1st, 2nd, and 3rd TAP scans according to the scan order of multiarterial phase as below. The applied techniques for acquisition of TAPs in one breath hold were originally described in a previous study of time resolved MR angiography for cerebral vessels ([@B18]). The applied technique consisted of contrast enhanced time robust angiography (CENTRA) ([@B17], [@B27]), keyhole, viewsharing ([@B18]) and the 2D parallel imaging technique with reduction factors of two in phase, and two in slice-encoding directions ([@B28]). In brief, a central K-space (Ky-Kz) is sampled repeatedly, and an elliptical-centric readout of the periphery of K-space is obtained as the last step of the acquisition ([@B29]) serving as the reference scan. To improve time resolution, elliptical central K-space is additionally divided into three keyhole fractions including central (C) and two peripheries (P^+^, P^-^) and the fractions are acquired in alternative repetition of C and P^+^ pair followed by C and P^-^ pair ([Fig. 1](#F1){ref-type="fig"}). The alternative acquisition between CP^+^ and CP^-^, and the pseudorandom order sampling in each fraction contribute to ensure that there is no discontinuity of signal intensity between K-space areas. The proportion of elliptical central K-space, which can be modified by users, was 20% in this study, and the viewsharing percentage (center of central K-space/the whole central K-space) was 60%. Alternation mode was not applied in our study, so as not to reduce data fidelity. The breath-hold time for the three arterial phases was 18 to 21 seconds, i.e., 6 to 7 seconds per phase.

Imaging Analysis
----------------

Two attending radiologists reviewed the images independently, and discrepant cases were reviewed additionally in consensus a week from the independent review session. All image reviews were performed using picture archiving and communication system workstations (Maroview 5.4, Infinitt, Seoul, Korea) with monitors having a spatial resolution of 1600 × 1200 (Totoku, Tokyo, Japan). The timing of the arterial phase was graded on a three point-scale ([@B9][@B16]): 1 = early arterial phase, only hepatic artery is opacified; 2 = late arterial phase, opacified hepatic artery and mild portal vein enhancement, without strong parenchymal enhancement or hepatic vein enhancement; 3 = portal venous phase, opacification of the portal vein, and opacification of the hepatic vein.

Respiratory motion artifacts were scored on a four point-scale ([@B9][@B16]): 1 = non-diagnostic due to severe motion; 2 = motion-related artifacts causing impaired diagnostic capability of the readers; 3 = noticeable motion-related artifacts with an image quality decrease, but no diagnostic performance impairment; and 4 = no or minimal artifacts. Typical feature of truncation artifact presented as ringing artifact along the liver margin is not considered as motion artifact ([@B30][@B31]). Otherwise, artifacts were considered as combination of motion artifact and truncation artifact, and scored accordingly. In patients who underwent liver MR including TAPs, image quality was also evaluated in addition to timing and respiratory motion in every phase. The overall image quality was graded on a four-point scale ([@B14]): score 1, diagnostically unacceptable; score 2, worse than average; score 3, average; and score 4, good and better than average. For comparison between single arterial phase and TAPs, the single phase of the best timing adequacy (score 2) was chosen among the three arterial phases, and the motion score of the determined best arterial phase was the representative motion score. If there were more than two arterial phases with the same timing adequacy, the highest motion score was selected.

Finally, one attending radiologist reviewed the arterial and transitional phases of all patients and classified them into \'no motion\', \'transitional\' or \'persistent\' motion categories depending on the presence of motion artifacts on the arterial phase as well as on the transitional phase([@B9]). Patients who showed motion artifacts on at least one arterial phase was regarded as patients with \'transient\' or \'persistent\' motion depending on the presence of motion on the transitional phase.

Statistical Analysis
--------------------

The χ^2^ test was performed to compare categorical variables and the Student *t* test or Mann-Whitney test was used for continuous variable comparison between single and TAPs, as appropriate. Comparison of motion artifacts, timing adequacy, and image quality was done among the scanners and three arterial phases using the Kruskal-Wallis test or Friedman analysis with pairwise comparison using Bonferroni correction. Agreement between the two reviewers for every item was evaluated using weighted kappa stastitics. A κ value of 0 indicated poor; 0.01--0.20, slight; 0.21--0.40, fair; 0.41--0.60, moderate; 0.61--0.80, good; and 0.81--1.00, excellent agreement ([@B32]). All statistical analyses were performed using commercially available software (MedCalc, version 12, MedCalc Software, Mariakerke, Belgium; IBM SPSS Statistics, version 22.0, SPSS Inc., Armonk, NY, USA). A *p* value \< 0.05 (*p* \< 0.017 in three comparisons after Bonferroni correction) was considered to indicate a statistically significant difference.

RESULTS
=======

In patients with TAP acquisition, the late arterial phase was achieved at least once in 96.4% (159/165) of patients; the late arterial phase was missed in 6 patients in whom only the early arterial phase (n = 1) and portal venous phase (n = 5) were obtained through TAPs. Capture of the late arterial phase was observed in 83% (137/165), 84.2% (139/165), and 73.3% (121/165) of the patients in the 1st, 2nd, and 3rd scans, respectively. In patients with conventional single arterial phase acquisition, the late arterial phase was observed in 84.2% (494/587, 81.4% \[276/339\] at 1.5T; and 87.9% \[218/248\] at 3T). In 12.6% (74/587) patients, the early arterial phase was obtained and the portal venous phase was captured in 3.2% of (19/587) patients ([Table 3](#T3){ref-type="table"}). In short, TAP acquisition showed a significantly higher chance of obtaining the late arterial phase compared to conventional, single arterial phase acquisition (96.4% \[159/165\] vs. 84.2% \[494/587\], *p* \< 0.001) ([Fig. 2](#F2){ref-type="fig"}).

Late arterial phase imaging without noticeable motion artifacts (motion score of 4) was obtained at least once in 86.1% (142/165) patients, and the late arterial phase without significant motion artifacts (motion score ≥ 3) was achieved at least once in 96.4% (159/165) of patients. In patients with single arterial phase, 60.0% (352/587) showed late arterial phase with motion score 4 and 19.9% (117/587) showed late arterial phase with motion score 3. In 156 patients who underwent TAP, 3.6% (6/165) patients showed missed late arterial phase or significant motion artifact (score ≤ 2) on all three scans, whereas the incidence was 20.1% (118/587) in single arterial phase acquisition. The rate of obtaining the late arterial phase without significant motion artifacts was significantly higher in TAP acquisition than in conventional single acquisition (96.4% \[159/165\] vs. 79.9% \[469/587\], *p* \< 0.001). In detail, among the 165 patients with TAP acquisition, the 1st scan showed higher motion artifact than the others (3.4 ± 0.8 on 1st, 3.8 ± 0.4 on 2nd, 3.8 ± 0.4 on 3rd, *p* \< 0.001) and showed lower image quality compared with the 2nd and 3rd scans (3.0 ± 0.8, 3.7 ± 0.6, 3.7 ± 0.6, respectively, *p* \< 0.001). However, the 2nd and 3rd scans did not show a significant difference of motion artifacts and image quality (*p* = 0.34, 0.20, respectively) ([Table 3](#T3){ref-type="table"}).

In the 165 patients who underwent TAP acquisition, noticeable motion artifacts (score ≤ 3) were significantly reduced on the 2nd and 3rd scans (13.9% \[23/165\] and 13.9% \[23/165\], respectively), compared with the 1st scan (40% \[66/165\]). In addition, compared with patients who underwent only single arterial phase (31.9% \[187/587\]), there was no significant difference between the single arterial phase and the 1st arterial scan of triple acquisition (*p* = 0.06). However, the 2nd and 3rd scans of triple acquisition showed less motion artifacts (3.6 ± 0.5, 3.5 ± 0.7, respectively) than the single arterial phase (2.8 ± 0.5, *p* \< 0.001, *p* \< 0.001, respectively). Significant motion artifacts (score ≤ 2) were observed in 13.3% (22/165), 1.2% (2/165), 4.8% (8/165) on 1st, 2nd, and 3rd scans of TAP acquisitions and 6.0% (35/587) of single phase acquisitions (*p* = 0.003, 0.02, 0.70, respectively). A detailed summary of the motion score and image quality was summarized in [Table 3](#T3){ref-type="table"}.

Among the 253 patients with noticeable motion, 235 patients (62 in the TAP group and 173 in the single arterial phase group) were categorized as the \'transient motion group\'. Among them, 56 patients showed significant motion during arterial phase (22 in the TAP group and 34 in the single arterial phase group). In 62 patients who underwent TAP acquisition, motion was most frequently observed in the 1st scan (48.4%, 30/62). Significant motion was limited on the 1st scan in 63.6% (14/22) of patients. The most frequently affected arterial phase timing was the late arterial phase (72.6%, 45/62) followed by the early arterial phase and early + late arterial phase (9.7%, 6/62), after matching the scan order with the captured arterial phase timing ([Table 4](#T4){ref-type="table"}, [Fig. 3](#F3){ref-type="fig"}). In one patient who showed motion artifacts (score 3) on only the portal venous phase, all three arterial scans were obtained on the portal venous phase due to missed timing ([Table 4](#T4){ref-type="table"}). In patients who underwent single arterial phase acquistion, the late arterial phase was the most frequently affected phase (75.7% \[131/173\]) ([Table 4](#T4){ref-type="table"}).

Reader agreement for the arterial phase and motion artifacts were good to excellent in arterial phase timing (0.80 in the 1st TAP scan, 0.92 in the 2nd TAP scan, 0.90 in the 3rd TAP scan, 0.91 in the conventional single phase), motion artifacts (0.78 in the 1st TAP scan, 0.90 in the 2nd TAP scan, 0.83 in the 3rd TAP scan, 0.86 in the conventional single phase), and image quality (0.85 in the 1st TAP scan, 0.73 in the 2nd TAP scan, 0.81 in the 3rd TAP scan).

DISCUSSION
==========

Our study results revealed that a combination of CENTRA, keyhole, viewsharing and the 2D parallel imaging technique contributed to the reliable attainment of the \"late arterial phase\" at gadoxetic acid-enhanced liver MRI, which is critical for the detection of hypervascular liver tumors, even though previously regarded as challenging ([@B9][@B14]). In our study, the proportion of capturing the late arterial phase was 96.4% (159/165) in patients with TAP acquisition, which was significantly higher than the 84.2% (494/587) in patients who underwent conventional single arterial phase acquisition (*p* \< 0.001). In fact, in previous studies, bolus-tracking methods such as the MR fluoroscopy-guided technique or the test bolus technique showed a higher rate of obtaining the optimal arterial phase than fixed delay scans ([@B33][@B34][@B35]). However, missed arterial phases were reported in more than 10--15% of patients even after using the bolus-tracking technique due to either operator dependent problem or patient-related variables such as cardiac output ([@B36]). In our study, the combination of single breath-hold TAP acquisition and MR fluoroscopy guided technique provided the optimal arterial phase in most patients on at least one of the three phases, and the rate of capturing the late arterial phase was higher than the success rate of TAP acquisition with a fixed delay ([@B9]), and in fact, comparable with five-arterial phase acquisition with a fixed-delay ([@B16]). Thus, our results may provide clinically valuable information on optimal arterial phase acquisition at gadoxetic acid-enhanced liver MRI.

In our study, high temporal resolution as well as high spatial resolution was achieved, i.e., a combination of alternating viewsharing to keyhole techniques reduced scan times while maintaining high spatial resolution. Furthermore, the pseudorandom sampling of each partition of central K-space contributed to ensuring that there were no signal discontinuities throughout the keyhole acquisition ([@B18]) or ringing artifacts ([@B27]). Previously, in order to solve the problem of transient severe motion in the arterial phase of gadoxetic acid-enhanced MR imaging, a similar approach of multiple arterial phase imaging was applied, but high spatial resolution was undervalued as high temporal resolution with relatively low spatial resolution was reported to be clinically feasible in a prior study ([@B9]). However, gadoxetic acid-enhanced liver MRI can serve as a problem-solving tool for challenging cases in clinical practice and preoperative imaging for liver malignancies ([@B37]). Given that high spatial resolution contributes to better image quality and conspicuity of lesions and anatomic structures for preoperative planning ([@B28][@B38][@B39]), achieving high temporal and spatial resolution MRI would be of clinical importance.

Another obstacle to achieving the optimal late arterial phase at liver MRI may be motion artifacts. Owing to the relatively long acquisition time of MRI compared with computed tomography, motion artifacts are often encountered in patients with limited breath-holding capacity ([@B40]). Furthermore, transient dyspnea or transient severe motion after contrast media administration has been more frequently reported in patients who undergo gadoxetic acid-enhanced liver MRI than extracellular agents ([@B10][@B15][@B40]). The incidence of motion-related artifact has varied in the literature ([@B10][@B29][@B40][@B41]), but one recent study reported that 39% of cases showed motion-related artifacts on the arterial phase at gadoxetic acid-enhanced MRI ([@B10]). Although transient dyspnea is a self-limited benign phenomenon, it should be avoided by protocol adjustment if possible as it frequently deteriorates the arterial phase image quality, which thereby would hamper the diagnosis, leading to repetition of the examination. Several risk factors including the presence of chronic liver disease and a history of transient dyspnea have been suggested ([@B9][@B10][@B41]), but a recent study reported that transient dyspnea is poorly predicted by any of the reported risk factors ([@B42]). Thus, such results may require implementation of the arterial phase sequence, which would be clinically feasible and applicable to most patients, not only for the high-risk group.

In our study, significant motion artifacts were observed in 7.6% (57/752) of patients during the arterial phase. In 35 patients who underwent conventional single arterial phase acquisition, not only image quality but also diagnostic performance was negatively affected on qualitative evaluation. However, in the remaining 22 patients who underwent TAP acquisition, only one patient had persistent significant motion artifacts, which affected the diagnostic performance of radiologists. Thus, TAP acquisition would provide appropriate arterial phase acquisition with appropriate arterial timing and reduced motion contamination.

Of note, we found that motion artifacts were observed on the 1st phase of the three arterial scans in all patients who had transient motion artifacts, i.e., none of the patients showed motion artifact limited to 2nd and 3rd TAP scans. Indeed, 48.4% (30/62) of patients with noticeable motion artifacts and 63.6% (14/22) of patients with significant motion artifacts were in the 1st TAP scan. Although we had a limitation in the determination of the timing of motion on the basis of reconstructed images due to viewsharing and sharing the reference scan throughout the reconstruction, it is likely that motion may occur only in the early period of the arterial phase when motion artifacts are restricted on the 1st TAP scan. Therefore, although we could not capture the onset timing of motion, our observation suggests that nearly half of the transient motion occurred in the early phase after contrast media injection, and would typically cease in a short period. Our study results seem to be discrepant with the literature reporting that the 3rd scan of consecutive three arterial phases has seen a significant proportion of motion artifacts compared with the 1st and 2nd TAP scans ([@B9]). We do not have sufficient data to explain the discrepancy between these two studies. However, we postulate that different acquisition methods might have contributed to our differing results; we used MR fluoroscopy guided arterial phase acquisition whilst 15 to 20 seconds a fixed-delay method was used in the literature ([@B9]). In addition, another possible cause might be that prolonged arterial phase acquisition time up to 23 seconds by obtaining three phases in the previous study ([@B9]) could have contributed to initiating or worsening motion artifacts on the last phase due to the patients\' shortage of breath-holding capacity.

Our study has several limitations. First, its retrospective nature may have had an inevitable bias. Second, the acquisition time of the TAP imaging (18--21 seconds) was not the same compared with that of single arterial phase imaging (17--19 seconds). Third, transient dyspnea occurring before starting arterial phase acquisition might have led to underestimation of its incidence. In addition, motion artifacts were assessed by image analysis indirectly which may have also led to underestimation of the incidence of transient motion. However, investigation of the incidence of transient dyspnea was not our primary goal; instead, we focused on the feasibility of multi-arterial phases in clinically problematic cases, not asymptomatic and clinically acceptable liver MRI. Fourth, contamination of truncation artifact might be a source of error to estimate motion artifact although we tried to minimize contamination. Fifth, one may argue that the techniques used in our study may not be as promising as newly introduced techniques such as compressed sensing. However, our study purpose is not comparing the superiority of a technique to another but investigating whether the techniques would contribute to achieving optimal arterial phase consistently. Finally, we did not evaluate additional values for detecting lesions on three arterial images. However, we showed an improved rate of obtaining reliable arterial phase imaging, which would be clinically valuable, contributing to the achievement of a thorough, full data set of gadoxetic acid-enhanced liver MRI.

In conclusion, TAP imaging may reliably provide adequate arterial phase imaging for gadoxetic acid-enhanced liver MRI.

![K-space acquisition scheme using combination of CENTRA, keyhole and viewsharing.\
K-space is divided into central (Kz-Ky) and peripheral portion (R), and central K-space is sampled repeatedly in random manner whilst peripheral K-space is acquired once last to serve as reference scan for each reconstruction (violet arrows). Central K-space is divided into three keyhole fractions including central (C) and two peripheries (P^+^, P^-^) and fractions are acquired in alternating fashion between combinations of (P^+^, C) and (C, P^-^). To avoid signal discontinuation, P^+^ or P^-^ of keyhole obtained on previous scan is added to reconstruction of next scan (orange arrows). CENTRA = contrast enhanced time robust angiography](kjr-17-522-g001){#F1}

![Triple arterial phase (TAP) of 80-year-old man with colon cancer.\
1st, 2nd, and 3rd TAP scans **(A-C)** provide early arterial phase **(A)** and two late arterial phases **(B, C)** with different parenchymal enhancement degrees.](kjr-17-522-g002){#F2}

![Fig. 3. Triple arterial phase of 70-year-old woman with colon cancer liver metastasis.\
1st scan was deteriorated by significant motion artifacts with truncation artifact, leading to non-diagnostic image **(A)**. Following 2nd **(B)** and 3rd **(C)** TAP scans were regarded as optimal late arterial phase imaging, and successfully demonstrate 4 cm rim enhancing mass which was confirmed as metastasis after surgery (arrows). TAP = triple arterial phase](kjr-17-522-g003){#F3}

###### Patient Characteristics

![](kjr-17-522-i001)

  Characteristics                          Multiple Arterial Phase Acquisition   Single Arterial Phase Acquisition   *P*
  ---------------------------------------- ------------------------------------- ----------------------------------- ----------
  No. of patients                          165                                   587                                 
  Sex (M:F)                                112:53                                392:195                             0.863
  Age                                                                                                                
   Men                                     60.6 ± 8.6 (31, 81)                   60.3 ± 10.6 (24, 89)                0.755
   Women                                   59.2 ± 12.0 (31, 80)                  59.8 ± 13.1 (27, 85)                0.788
  Mean BMI                                 23.4 ± 3.0 (16.1, 32.5)               23.1 ± 3.5 (13.6, 40.1)             0.454
  Lung disease (%)                         3.6 (6/165)                           2.4 (14/587)                        0.567
   Lung cancer                             0 (0/165)                             1.2 (7/587)                         0.339
   COPD                                    0.6 (1/165)                           0 (0/587)                           0.507
   ILD                                     0 (0/165)                             0.2 (1/587)                         0.588
   Metastasis                              2.4 (4/165)                           0.9 (5/587)                         0.252
   Others^\*^                              0.6 (1/165)                           0.2 (1/587)                         0.980
  Pleural effusion (%)^†^                  0 (0/165)                             1.9 (11/587)                        0.16
  Chronic liver disease (CLD, %)           67.3 (111/165)                        76.0 (446/587)                      0.031
   Child class (CLD or A:B:C)              99:12:0                               372:54:20                           0.172^§^
  Ascites (%)^†^                           2.4 (4/165)                           6.1 (36/587)                        0.093
  Bile duct obstruction (%)                0.6 (1/165)                           1.5 (9/165)                         0.609
  CT contrast media hypersensitivity (%)   9.7 (16/165)                          13.1 (77/587)                       0.299
  History of transient dyspnea (%)         15.2 (25/165)                         12.8 (74/587)                       0.502
  1st liver MR (%)                         49.7 (82/165)                         49.6 (291/587)                      0.948
  Oncologic disease (%)^‡^                 30.9 (51/165)                         20.1 (118/587)                      0.005

Values are presented as mean ± standard deviation (range). ^\*^One pulmonary ateriovenous malformation and one tuberculosis, ^†^Moderate to large amount, ^‡^Any oncologic disease except hepatocellular carcinoma, ^§^Comparison between two groups regarding incidence of child B or C to child A. BMI = body mass index, COPD = chronic obstructive lung disease, ILD = interstitial lung disease

###### Scan Parameters of Fat Suppressed 3D T1-Weighted APs in Each MR Scanner

![](kjr-17-522-i002)

  Parameter                      Scanner 1               Scanner 2               Scanner 3
  ------------------------------ ----------------------- ----------------------- -----------------------
  Scanner                        Ingenia                 Signa HDx               Magnetom Verio
  Field strength                 3T                      1.5T                    3T
  Repetition time (msec)         3.2                     5.1                     3.4
  Echo time (msec)               1.6                     2.2                     1.2
  Flip angle (°)                 10                      12                      11
  No. of arterial phase scan     3                       1                       1
  Delay for AP acquisition       MR fluoroscopy guided   MR fluoroscopy guided   MR fluoroscopy guided
  Slice thickness (mm)           4--6                    4--6                    4--6
  Reconstruction interval (mm)   2--3                    2--3                    2--3
  Field of view (cm)             399 × 399               350 × 350               380 × 309
  Matrix                         384 × 384               320 × 256               384 × 250
  Parallel acceleration factor   2 × 2                   2 × 1                   2 × 1
  Acquisition time               18--21 sec              17--19 sec              17--19 sec

AP = arterial phase, 3D = three-dimensional

###### Captured Arterial Phase, Motion Artifacts, and Image Quality in Triple Arterial Phase (TAP) and Conventional Single Arterial Phase Acquisition
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                                   Triple Arterial Phase Acquisition (n = 165)        Single Arterial Phase Acquisition (n = 587)                          
  -------------------------------- -------------------------------------------------- --------------------------------------------- ---------------------- ----------------------
  Captured arterial phase timing                                                                                                                           
   Early arterial phase (%)        13.9 (23/165)                                      5.5 (9/165)                                   0.6 (1/165)            12.6 (74/587)
   Late arterial phase (%)         83 (137/165)                                       84.2 (139/165)                                73.3 (121/165)         84.2 (494/587)
   Portal venous phase (%)         3 (5/165)                                          10.3 (17/165)                                 26.1 (43/165)          3.2 (19/587)
  Degree of motion artifact                                                                                                                                
   Motion score 1 (%)              3 (5/165)                                          0 (0/165)                                     0 (0/165)              0.7 (4/587)
   Motion score 2 (%)              10.3 (17/165)                                      1.2 (2/165)                                   4.8 (8/165)            5.3 (31/587)
   Motion score 3 (%)              26.7 (44/165)                                      12.7 (21/165)                                 9.1 (15/165)           25.9 (152/587)
   Motion score 4 (%)              60 (99/165)                                        86.1 (142/165)                                86.1 (142/165)         68.1 (400/587)
  Qualitative analysis             In all subjects                                                                                                         
  (n = 165)                        (n = 587)                                                                                                               
   Motion artifacts                3.4 ± 0.8 (1.0, 4.0)                               3.8 ± 0.4 (2.0, 4.0)                          3.8 ± 0.4 (2.0, 4.0)   3.6 ± 0.6 (1.0, 4.0)
   Image quality^†^                3.0 ± 0.8 (1.0, 4.0)                               3.7 ± 0.6 (1.0, 4.0)                          3.7 ± 0.6 (1.0, 4.0)   N/A
  Qualitative analysis             In patients with noticeable motion artifacts^\*^                                                                        
  (n = 66)                         (n = 187)                                                                                                               
   Motion artifacts                2.6 ± 0.6 (1.0, 3.0)                               3.6 ± 0.5 (2.0, 4.0)                          3.5 ± 0.7 (2.0, 4.0)   2.8 ± 0.5 (1.0, 3.0)
   Image quality^†^                2.3 ± 0.7 (1.0, 4.0)                               3.3 ± 0.8 (1.0, 4.0)                          3.3 ± 0.8 (1.0, 4.0)   N/A
  Qualitative analysis             In patients with significant motion artifact^‡^                                                                         
  (n = 22)                         (n = 35)                                                                                                                
   Motion artifacts                2.0 ± 0.6 (1.0, 3.0)                               3.3 ± 0.7 (2.0, 4.0)                          3.4 ± 0.7 (2.0, 4.0)   1.9 ± 0.3 (1.0, 2.0)
   Image quality^†^                1.9 ± 0.5 (1.0, 3.0)                               3.0 ± 0.9 (1.0, 4.0)                          3.0 ± 1.0 (1.0, 4.0)   N/A

Values are presented as mean ± standard deviation (minimum, maximum). ^\*^Noticeable motion artifacts indicate motion artifact scores of 1 to 3, ^†^Image quality was evaluated in triple arterial phase acquisition, ^‡^Significant motion artifacts indicate motion score of 1 or 2. N/A = not available

###### Frequency of Motion Artifacts at Each Scan and Captured Arterial Phase Timing in 225 Patients with Only Transient Motion Artifacts

![](kjr-17-522-i004)

                                                            Triple Arterial Phase Acquisition   Single Arterial Phase Acquisition                    
  --------------------------------------------------------- ----------------------------------- ----------------------------------- ---------------- --------------
  Incidence of observed motion artifacts at each scan^\*^                                                                                            
   1st TAP scan only (%)                                    48.4 (30/62)                        63.6 (14/22)                        N/A              N/A
   2nd TAP scan only (%)                                    0 (0/62)                            0 (0/22)                            N/A              N/A
   3rd TAP scan only (%)                                    0 (0/62)                            0 (0/22)                            N/A              N/A
   1st + 2nd TAP scans (%)                                  16.1 (10/62)                        4.5 (1/22)                          N/A              N/A
   1st + 3rd TAP scans (%)                                  19.4 (12/62)                        22.7 (5/22)                         N/A              N/A
   2nd + 3rd TAP scans (%)                                  0 (0/62)                            0 (0/22)                            N/A              N/A
   1st, 2nd, and 3rd TAP scans (%)                          16.1 (10/62)                        4.5 (1/22)                          N/A              N/A
  Timing of motion artifact                                                                                                                          
   Early arterial phase (%)                                 9.7 (6/62)                          27.3 (6/22)                         22 (38/173)      29.4 (10/34)
   Late arterial phase (%)                                  72.6 (45/62)                        54.5 (12/22)                        75.7 (131/173)   70.6 (24/34)
   Portal venous phase (%)                                  1.6 (1/62)                          0 (0/22)                            2.3 (4/173)      0 (0/34)
   Early + Late (%)                                         9.7 (6/62)                          13.6 (3/22)                         N/A              N/A
   Late + Portal (%)                                        4.8 (3/62)                          4.5 (1/22)                          N/A              N/A
   Early + Late + Portal (%)                                1.6 (1/62)                          0 (0/22)                            N/A              N/A

^\*^Evaluated only in patients who underwent triple arterial phase acquisition. N/A = not applicable, TAP = triple arterial phase
